Perhaps to expand the Botox business...testing has been done for the use of Botox for over active bladders and migraines so perhaps this falls into the plan to expand treatment revenues for over active bladders with some new technology...BD
Allergan Inc.s interest in unmet medical needs has led it to a new market. The Irvine-based drug maker is paying $370 million for Esprit Pharma Inc., a New Jersey maker of a drug to treat overactive bladders. Allergans paying cash for Esprit, which is privately held. The deals expected to close in the fourth quarter. Lazard Capital Markets analyst Alexander Arrow believes the Esprit deal is setting the stage for another potential use for Allergans longtime flagship Botox.
Sanctura is expected to do $40 million to $48 million in sales this year. Allergan thinks the drug has the potential to do $300 million to $400 million in yearly sales.
The drug is taken twice a day to treat overactive bladder. The Food and Drug Administration also has approved a once-a-day version.
0 comments :
Post a Comment